Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Chalice Brands Ltd CHALF

Healthcare Drug Manufacturers - Major Cannabis
Chalice Brands Ltd. is a U.S. operator in the most competitive, innovative and mature cannabis market in North America. Leaders in retail, marketing and craft cultivation supported by fully integrated processing and distribution. The Company has 12 retail stores in Oregon operating as Chalice Farms, Homegrown Oregon and Left Coast Connection and is distributed nationally through Fifth & Root.


GREY:CHALF - Post by User

Chalice Brands Ltd
Bullboard Posts
User Avatar Image
(0)
•••
Comment by slimjim11on Apr 14, 2016 12:10pm
53 Views
Post# 24766656

RE:then add potential risk from fda warning letters

RE:then add potential risk from fda warning lettersSmartStadium, I don't see the relevance of posting a link to a news story from February 16, which describes warnings sent to companies making cannabis related health claims prior to the publication of the GW Pharma clinical results. Please enlighten us all what the relevance is here?
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities